INTERVIEW: SillaJen CEO Confident On ‘Dream’ Cancer Therapy (Pt. 1)

After years of convincing the medical industry about the value of its novel cancer immunotherapy, South Korea’s SillaJen may be stepping closer to its goal of commercializing the “dream cancer therapy.” The bioventure’s CEO shared his views on the product and SillaJen’s future in the first part of this exclusive interview with PharmAsia News.

SEOUL – Following a green light from the U.S. FDA to begin an international Phase III clinical trial with its novel liver cancer therapy, SillaJen Inc. said preparations for the study are proceeding smoothly and if things proceed as planned, it expects to begin commercialization earlier than originally scheduled.

"When completely cured advanced cancer patients or CR [complete remission] patients begin to appear around the world, then the Phase III trials will end early and we will be able to launch the product," Moon Eun-sang, CEO of

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia